Date of Report (Date of earliest event reported): January 4, 2019

CORINDUS VASCULAR ROBOTICS, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware 001-37406 30-0687898
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

309 Waverley Oaks Road, Suite 105
Waltham, MA 02452
(Address of Principal Executive Office) (Zip Code)

Registrant's telephone number, including area code: (508) 653-3335

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth Company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.

Corindus Vascular Robotics, Inc. is furnishing as Exhibit 99.1 to this Current Report on Form 8-K an investor presentation which will be used, in whole or in part, and subject to modification, on January 4, 2019 and at subsequent meetings with investors or analysts.

The information in this Current Report on Form 8-K (including the exhibit) is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor will any of such information or exhibit be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<table>
<thead>
<tr>
<th>Exhibit Number</th>
<th>Description</th>
</tr>
</thead>
</table>
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: January 4, 2019

CORINDUS VASCULAR ROBOTICS, INC.

By:  /s/ David W. Long

David W. Long
Chief Financial Officer
Corindus Vascular Robotics (CVRS)
January 2019
Forward Looking Statements

This presentation contains "forward-looking statements" (as such term is defined in Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended), and information relating to the company, that are based on the current beliefs of, and assumptions made by our management and the information currently available to our management. Forward-looking statements relate to expectations concerning matters that are not historical facts. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict," "opinion," "will" and similar expressions and their variants, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to statements related to our expected business, products and adoption of robotic medical procedures, including Ablation, telestenting and remote procedures, and expanding our technology platform for use in the neurovascular market; results of operations; future financial condition; ability to increase our revenue; and similar matters. These forward-looking statements should be considered in light of various important factors, including, without limitation, our ability to expand our technology platform and achieve the advances necessary for intraoperative and remote procedures, including in humans; our ability to expand our technology platform for use in other segments of the vascular intervention market; including neurointerventional and other more complex cardiac interventions; obtaining necessary regulatory approvals for the use on humans and marketing of our products in the United States and in other countries; the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the impact of global and regional economic and credit market conditions on health care spending; health care reform legislation in the United States and its impact on hospital spending, reimbursement and fees which will be levied on certain medical device revenues; decreases in hospital admissions and actions by payors to limit or manage surgical procedures timing and success of product development and market acceptance of developed products; procedure counts; regulatory approvals, clearances and restrictions; guidelines and recommendations in the health care and patient communities, intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which we operate; the inability to meet demand for products; the results of legal proceedings to which we are or may become a party; product liability and other litigation claims; adverse publicity regarding our company and safety of our products and the adequacy of training; our ability to expand in foreign markets and other risk factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on current expectations and are subject to risk, uncertainties and assumptions that are difficult to predict, including those risk factors described in the Company’s Annual Report on Form 10-K for the fiscal year ended on December 31, 2017. Our actual results may differ materially and adversely from those expressed in any forward looking statements. We undertake no obligation to publicly update or release any revisions to these forward-looking statements except as required by law.
Corindus: An Overview
A Global Leader in Robotic-assisted Vascular Interventions

Commercialization of CorPath GRX in 2017 was a Key Inflection Point, Accelerating Physician Adoption

- 2012: Corindus, Inc. (CorPath)
- 2014: FDA Clearing CorPath 300 for use in PCI
- 2016: Q4
- 2017: Record Robotics Placed in 2017, 28 systems placed in first year of GRX commercialization
- 2018: Moyo Teleintervention Partnership established to explore worldwide expansion
- 2018: FDA Clears 1st Automated Robotic Module (RMB), first step towards full procedural automation
- 2018: FDA Clears CorPath GRX for use in PVI
- 2018: Total Physicians Trained w/ Second Generation GRX

Room to Grow: YTD <1% of potential target physician population trained on GRX

Company Goes Public trading on NYSE as CVS

M&A Activity: Acquisition of Cardiovascular Technology in 2018

PNDA Approval in Japan commencing in 2018
Corindus’ Robotic Technology
Potential to be First Disruptive Treatment Option in Vascular Medicine in 40+ years

Corindus’ Goal is to be the First Robotics System for All Major Vascular Markets

1 CorPath Systems are not indicated for use in neuro interventions.
Adding Value in PCI & Peripheral Across Key Stakeholders

Paradigm Shift in Place Will Drive Adoption

**Hospital**
- Grow Patient Volume – 1/mo.
- Safe Work Environment
- Patient Satisfaction
- Telerobotics Expansion

**Patient**
- Less Radiation Exposure
- More Precise Treatment
- Faster & More Comfortable Recovery
- Treated Locally

**Physician**
- Reduces Burnout
- Extends Career
- Attracts Physician Talent
- Extends Physician Reach
Substantial Market Opportunity
Targeting Subsets Where Technology Platform Adds Value

**PCI**
3+ M Procedures WW
(~900K US / ~2.2M OUS)

**PERIPHERAL**
Over 2+ M Procedures WW
(~875K US / ~1.3M OUS)

**NEURO**
~900K Stroke Incidence US

Target Market:
US (Complex) / OUS (Simple / Complex)

Target Market:
CLI (OTK)

Target Market:
Expand TAM with remote access

---

1 National Research Group. prostate cancer market size in fiscal year 2023 only.
2 Division of Cardiology.
3 Consider patient based on diagnostic report.
Growing Interest Among Clinicians

Major activity in all vascular markets

- Largest ever presence of robotics at TCT
- Strong positive response to multiple live cases marked shift in sentiment
- Performed the first live remote PCI “telestenting” procedure at a conference in a porcine model

- Executive and R&D attendance
- Engaged with large number of neuro physicians generating tremendous excitement for remote stroke application

- Launch event for robotic CLI
- Premier suite with 2 simulators and R&D tech showcase
- Taped case presentation by course director Dr. Jihad Mustapha
Robotics Integrates Into High Tech Care Models

Allow Procedures to be Performed
**Procedural Automation**

**Problem**
- High percentage of procedure time is dedicated to wire manipulation
- Varying skill levels among operators

**Strategy**
- Create algorithms based on techniques of highly skilled operators
- Reduced procedure time may positively impact patient outcomes

**Continued development of technIQ Series**

Now automated movements aimed at reducing navigation time, increasing success of lesion crossing.
### Addressing Unmet Needs with Telerobotics

<table>
<thead>
<tr>
<th>The Problem</th>
<th>Our Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergent procedures: Time to treatment is critical</td>
<td>Reduce time to treatment for emergent procedures such as STEMI and stroke</td>
</tr>
<tr>
<td>Access to expertise &amp; treatment is geographically limited</td>
<td>Increase access to care globally</td>
</tr>
<tr>
<td>Shortage of skilled specialists</td>
<td>Expand intervention- &amp; thrombectomy-capable facilities</td>
</tr>
<tr>
<td>Incidence of STEMI &amp; stroke on the rise due to aging patient population</td>
<td>Enable tele-proctoring &amp; scale tele-diagnostic capabilities to tele-treatment</td>
</tr>
</tbody>
</table>
### Remote Technology Development

#### Achievements & Milestones

**2018**

<table>
<thead>
<tr>
<th>Q1 2018</th>
<th>Q2 2018</th>
<th>Q3 2018</th>
<th>Q4 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Technology Development</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Realtime fluoroscopy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Realtime telemetry</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Telemonitoring system</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Network monitoring tool</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Product Development</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>100 Mile Remote PCI Case</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>5G Pilot</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>First Human Use Case</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>End User Testing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Preclinical Labs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Live Remote Case</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Corindus</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>tct2018</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

![Remote operator site approximately 20 miles from ApeX Heart Institute](image-url)
The Telerobotic Intervention Study
First-in-human remote coronary intervention

December 4th and 5th, 2018
5 patients received successful PCI procedures with remote operator, Dr. Tejas Patel, at a distance of ~20 mi (32km) away.
Neurovascular Steering Committee / Milestones

Product Optimization for Remote Stroke Underway

Steering Committee

CMO, Neuro

Apolline S. Tart, D.O.
Greenville Health System

Ricardo A. Hanel, M.D. Ph.D.
Baptist Health System

Tafari G. Jusow, M.D.
University of Pittsburgh Medical Center

J. Mocco, M.D.
Mt. Sinai Hospital

Raul A. Negron, M.D.
Grady Memorial Hospital

Vitor Neves Pereira, M.D.
Touhy/Virginia Hospital

Adnan Siddiqui, M.D.
Toshiba Stroke & Vascular Research Center

Satoshi Takahiro, M.D.
Ronal Reagan-UCCLA Medical Center

Raymond C. Turner, M.D.
Greenville Health System

2018

- KOL Neuro Summit
- Steering Committee Formed
- Multiple Neuro Animal Lab Studies

2019

- CorPath GRX FDA Submission
- GRX Neuro Product Launch
- Neuro Remote Robotic Development

1 Expected timing
Stroke: Time to Treatment is Key

1 minute = ~2 million lost neurons

7+ million stroke survivors¹
5th Leading cause of death in the US (1 in 19 deaths)¹
2/3 With a moderate-to-severe disability¹
1 second Ages a patient by 9 hours¹

¹ American Heart Association; Heart Disease and Stroke Statistics 2021 Update. AHA
Remote Access Capabilities May Significantly Increase TAM

- Treatment within 24 hours is critical
- Yet only a fraction of patients (~35K) are treated due to:
  - Lack of proximity to facilities
  - Limited number of specialists
- Rapidly expanding market expected to grow from $1B today to $2.6B by 2028

Remote Access Capabilities: Multiple Growth Opportunities

- Increase patients treated with remote access
- Expand market further with next generation robot

Potential to Significantly Expand Treatable Patients: More Procedures in a Growing Market

---

1. Corindus estimates based on third party report
2. Millennium Research Group
Financials Snapshot

Revenue

GRX Installed Base

Cassette Sales

- Cash balance of $23.9M, Debt of $11.7M, 161.2M shares outstanding and 1M preferred (convertible to 20.9M common shares) as of September 30, 2019
- Sites that upgraded from a CorPath 200 to a CorPath GRX have, on average, nearly doubled the percentage of PCI procedures performed robotically
Clinical Catalysts: Next 12-24 Months

Key Expected Milestones for Clinical Development

Remote
✓ Completed live remote PCI at TCT in Q3 2018
✓ First-in-human completed in December 2018 in India
• First U.S. in-human remote case in 2019
• Approval of the next series of automated movements in the technIQ Series

Neuro
• FDA submission for neuro indication by early 2019
• Proof of principle for a remote stroke robotic system in 2019
• Partnership for commercialization and co-development
• FDA clearance and launch of CorPath GRX for neuro in 2019
Corindus Summary / Key Investment Thesis

- Significant progress in technology development and clinical expansion is creating a burning platform for hospitals to build a robotic program
- AI / automation and remote access have the potential to add significant value to hospitals, patients, and doctors in the interventionalist market
- Remote capabilities have the ability to increase TAM of the stroke market with opportunity to further expand the addressable market post launch of the next generation robot
- Strong intellectual property portfolio / first mover advantage

Corindus is a Leading Vascular Robotics Company with Opportunities in Coronary, Peripheral, and Neurovascular Markets